GSK (GSK) announced that its regulatory application for Arexvy, has been accepted for review by China’s Center for Drug Evaluation, CDE, for the prevention of lower respiratory tract disease, LRTD, caused by respiratory syncytial virus, RSV, in adults aged 60 years and older. If approved, Arexvy will be the first vaccine available to this population in China to help protect against the potentially serious consequences of RSV disease.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK price target raised to 2,250 GBp from 1,900 GBp at Citi
- GSK price target raised to 2,350 GBp from 2,100 GBp at BofA
- GSK price target raised to $70 from $55 at TD Cowen
- Balancing Blenrep Upside With Valuation and Execution Risks: Why the Risk‑Reward Remains a Hold
- Balancing Strategic Promise and Execution Risk: Justifying a Hold Rating on GSK